Get started

Financials · COCP

Cocrystal Pharma Inc. (COCP) financials

For the twelve months ended Jun 30, 2026, Cocrystal Pharma Inc. reported -$9.94M of net income.

Net income, TTM
-$9.94M
EPS, diluted, TTM
-$0.75
Cash
$2.17M
Market cap
$21.4M
Annual revenue$2.01M
FY2016FY2020
Annual net income-$8.83M
FY2016FY2025
Annual free cash flow-$8.20M
FY2016FY2025

COCP revenue and earnings growth

COCP revenueQ2 2026$105.0K

QoQ
-53.3%
FY YoY
-69.3%
5Y CAGR
+62.1%

COCP revenue was $105.0K in fiscal Q2 2026 (ended Jun 30, 2026), down 53.3% from the prior quarter. For the full fiscal 2020 it was $2.01M, down 69.3% from fiscal 2019. Compound annual growth was +62.1% over 5 years.

COCP net incomeQ2 2026-$3.16M

COCP net income was -$3.16M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.06M a year earlier. For the full fiscal 2025 it was -$8.83M, compared with -$17.50M in fiscal 2024.

COCP EPSQ2 2026-$0.23

COCP diluted EPS was -$0.23 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.20 a year earlier. For the full fiscal 2025 it was -$0.78, compared with -$1.72 in fiscal 2024.

COCP free cash flowQ4 2025-$1.74M

COCP free cash flow was -$1.74M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$3.16M a year earlier. For the full fiscal 2025 it was -$8.20M, compared with -$16.49M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue-----$2.01M$6.56M--$7.0K$126.0K
Research and development$5.05M$12.54M$15.17M$12.39M$8.79M$6.03M$4.00M$4.67M$5.82M$101.68M
Selling, general and admin$3.96M$5.34M$5.99M$5.75M$5.43M$5.57M$4.86M$4.35M$2.44M$4.14M
Operating income-$9.02M-$17.88M-$18.56M-$38.83M-$14.22M-$9.59M-$48.41M-$62.92M-$8.26M-$105.82M
Interest expense-$134.0K-$537.0K-$640.0K$2.0K$4.0K$8.0K$19.0K$58.0K--
Pre-tax income-$8.83M-$18.63M----$9.65M-$48.17M-$62.63M-$7.49M-$104.27M
Income tax--------$13.58M-$6.88M-$29.39M
Net income-$8.83M-$17.50M-$17.98M-$38.84M-$14.19M-$9.65M-$48.17M-$49.05M-$613.0K-$74.87M
EPS, basic-$0.78-$1.72-$1.87-$4.77-$0.16-$0.17-$1.51-$1.75-$0.03-$3.18
EPS, diluted-$0.78-$1.72-$1.87-$4.77-$0.16-$0.17-$1.51-$1.75-$0.03-$3.30
Diluted shares11.3M10.2M9.7M8.1M88.4M55.2M31,85928,00924.1M23.5M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$7.03M$9.86M$26.35M$37.14M$58.70M$33.01M$7.42M$2.72M$748.0K$3.64M
Receivables-----$556.0K$644.0K-$1.0K$21.0K
Current assets$8.13M$11.58M$29.09M$40.18M$59.32M$34.02M$8.28M$2.94M$2.18M$5.47M
Goodwill----$19.09M$19.09M$19.09M$65.19M$65.19M$65.19M
Total assets$9.71M$13.46M$31.26M$40.84M$79.39M$54.24M$28.53M$68.56M$121.43M$124.88M
Current liabilities$2.21M$2.43M$3.26M$1.22M$1.54M$1.36M$2.29M$1.56M$1.44M$2.04M
Total liabilities$3.38M$3.93M$4.88M$1.27M$1.84M$1.74M$2.82M$1.67M$16.03M$22.56M
Shareholders' equity$6.33M$9.52M$26.38M$39.60M$77.55M$52.51M$25.71M$66.89M$105.40M$102.32M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$8.19M-$16.48M-$14.67M-$21.43M-$12.72M-$9.83M-$1.56M-$8.29M-$6.90M-$14.65M
Capital expenditures$12.0K$8.0K$118.0K$74.0K$52.0K$240.0K$145.0K$28.0K$40.0K$51.0K
Free cash flow-$8.20M-$16.49M-$14.78M-$21.51M-$12.77M-$10.07M-$1.71M-$8.32M-$6.94M-$14.71M
Investing cash flow-$12.0K-$8.0K-$118.0K-$74.0K-$52.0K-$240.0K-$145.0K$1.37M-$40.0K$3.0K
Financing cash flow$5.37M-$3.99M-$27.0K$38.47M$35.66M$6.42M$8.89M$4.08M$9.02M
Stock-based compensation$270.0K$643.0K$801.0K$855.0K$724.0K$662.0K$351.0K$562.0K$614.0K$548.0K
Depreciation and amortization$72.0K$126.0K$189.0K$185.0K$190.0K$157.0K$98.0K$50.0K$101.0K$201.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY------69.3%---105.6%-30.0%
Operating margin------476.0%-737.4%---83983.3%
Net margin------479.0%-733.8%---59423.8%
Free cash flow margin------500.0%-26.0%---11671.4%
Return on equity-139.5%-183.8%-68.2%-98.1%-18.3%-18.4%-187.4%-73.3%-0.6%-73.2%
Return on assets-90.9%-130.1%-57.5%-95.1%-17.9%-17.8%-168.8%-71.5%-0.5%-60.0%
Current ratio3.684.778.9233.0438.4025.053.621.891.512.68

Source: XBRL data Cocrystal Pharma Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported Mar 21, 2018.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

COCP peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
COCP---$9.94M-$21.4M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

COCP FAQ

6 questions
  • Is COCP profitable?
    No. Cocrystal Pharma Inc. reported a net loss of $9.94M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does COCP have?
    Cocrystal Pharma Inc. reported $2.17M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is COCP revenue growing?
    Cocrystal Pharma Inc.'s revenue changed -69.3% in fiscal 2020, to $2.01M. Its compound annual growth rate was +62.1% over 5 years.
  • What is COCP earnings per share?
    Diluted earnings per share were -$0.75 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did COCP last report financial results?
    The latest statements here come from Cocrystal Pharma Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this COCP financial data come from?
    Quantisnow builds these statements from the structured XBRL data Cocrystal Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.